Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EAGD T-cell Infusion Following Haploidentical HSCT
NCT03533816Phase 1Recruiting
- Sponsor
- University of Kansas Medical Center
- Start
- Jan 2020
- Primary completion
- Jan 2027
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of EAGD T-cells in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) and 1 more (2 arms), sponsored by University of Kansas Medical Center. Primary endpoints: Dose-limiting toxicity at 30 days, Severe acute adverse events at 100 days and 1 more. Started Jan 2020; status: recruiting.
02
Drugs
EAGD T-cells
03
Conditions
acute myeloid leukemia (AML)chronic myeloid leukemia (CML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03533816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03533816.